CorMedix Inc. (CRMD)
Nasdaq: CRMD · Pharmaceutical Preparations · Parsippany, NJ · filing with the SEC since 2007
Grade6.3
◀ Past 4.7● Present 6.8▶ Future 7.4
Who owns CorMedix Inc.
As filed with the SECHolders of 5% or more
3
Deep Track Capital, LP holds 7.94% of Common stock, $0.001 par value, as its SCHEDULE 13G/A filed May 15, 2026 says.
Directors and officers
11
report now, of 28 people on the record since 2010. Their holdings as a group are not read here.
Institutions as a whole
n/a
The record does not read the share held by managers that file Form 13F, so none is printed and no split of the rest is estimated. What it holds is the 3 named at left.
Holders of 5% or moreshare of the class, as filed
Deep Track Capital, LP
SCHEDULE 13G/A · filed May 15, 2026 · Common stock, $0.001 par value · 6.29% in Dec 1, 2025
Blackrock, Inc.
SCHEDULE 13G/A · filed Feb 5, 2025 · Common Stock
Shaibatalhamd Aymen Abdalkader
SCHEDULE 13G/A · filed Jun 12, 2026 · COMMON STOCK, PAR V ALUE $0.001 PER SHARE · 5.9% in Jun 12, 2026
The Vanguard Group
SCHEDULE 13G/A · filed Mar 26, 2026 · Common Stock · reported falling below 5%
What CRMD reports owning in othersstakes of 5% or more, and other ties
Talphera, Inc. TLPH
SCHEDULE 13D · filed Sep 12, 2025 · Common Stock
Other ties the annual report names
Acquisition of Melinta
A company bought · acquisition · owns, named in the 10-K filed Mar 5, 2026
6 subsidiaries in 1 country, from the list filed with the 10-K filed Mar 5, 2026.
Insider tradesForm 4
8sales
1purchases
5sales on a scheduled plan
4people selling
$2.6Msold, in dollars
$300,000bought, in dollars
Open-market trades on Form 4 from Sep 30, 2025 to Sep 30, 2026. A scheduled plan is a selling program set in advance under SEC rule 10b5-1. The trades are listed as filed and do not feed the grade.
By calendar yearSoldBought
2026 runs to Sep 30, 2026. Dollars as filed, summed by the transaction date.
People who traded in the window5 of 28 on the roster
| Person | Role as filed | Sales | Sold | On a plan | Buys | Bought |
|---|---|---|---|---|---|---|
| Dillione Janet | director | 5 | $1.5M | 3 | 0 | $0 |
| Lefkowitz Steven W | Interim Chief Financial Ofcr | 1 | $500,000 | 0 | 0 | $0 |
| Todisco Joseph | Chief Executive Officer | 1 | $400,000 | 1 | 0 | $0 |
| Dunton Alan W | director | 1 | $300,000 | 1 | 0 | $0 |
| Kaplan Myron | director | 0 | $0 | 0 | 1 | $300,000 |